A Double-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of PXL770, Including an Open-label, One-sequence Part to Assess the Drug-drug Interaction With Rosuvastatin in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2018
At a glance
- Drugs PXL 770 (Primary) ; Rosuvastatin
- Indications Metabolic disorders; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Poxel
- 23 Aug 2018 Status changed from recruiting to completed.
- 18 Jul 2018 Results (n=60) presented in a Poxel media release.
- 10 Jul 2018 According to a Poxel media release, data from this trial is expected in July 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History